The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

Adding an ICI to neoadjuvant chemotherapy can improve pCR rates and may improve OS in patients with MIBC, research suggests.

This trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus particle therapy is a safe and synergistically effective treatment in patients with ...

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus FLOT yields better outcomes than FLOT alone.

Durvalumab is an IV drug that boosts the immune system’s ability to detect and kill cancer cells. It’s used to treat a range ...

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, ...

An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...